Health & Environment
FDA Approves Hibsago As First-Of-Its-Kind Treatment For Chronic Hepatitis B
The Indian Express1h
THE BRIEF
1
The US FDA approved Hibsago injection on October 20, 2026, as the first antisense oligonucleotide treatment for certain adults with chronic hepatitis B without cirrhosis.
2
In clinical trials, 24 percent of patients receiving Hibsago met criteria to stop existing antiviral medicines, with 19 percent maintaining viral control twenty-four weeks later.
3
Common side effects include injection site reactions, fever, fatigue, and headache, alongside warnings regarding liver reactions and low platelet counts.